Copy
See below for a daily digest of the latest Pulmonary Hypertension news in Texas!

Ochsner Health’s New Orleans Facility Obtains PH Association Accreditation

Mar 05, 2018 07:00 am | Carolina Henriques

 

Ochsner PH facility accreditedAn Ochsner Health System facility in New Orleans has received Pulmonary Hypertension Association  care center accreditation. The association accredits care centers that can assure patients receive top PH diagnosis and treatment. Ochsner’s PH program is located at the John Ochsner Heart and Vascular Institute. It is one of only two accredited programs in Louisiana, Mississippi and Alabama. The institute is […]

The post Ochsner Health’s New Orleans Facility Obtains PH Association Accreditation appeared first on Pulmonary Hypertension News.

Read More
share on Twitter Like Ochsner Health’s New Orleans Facility Obtains PH Association Accreditation on Facebook

Those Who Care for Rare Disease Patients Face Burnout, First US Survey Shows

Mar 02, 2018 07:30 am | Patricia Inacio, PhD

 

Rare disease caregiversFamily and friends caring for people with rare diseases face emotional, financial, physical, and social burnout, partly because outside sources of support are limited, the first-of-its-kind U.S. survey shows. Global Genes and the National Alliance for Caregiving released the findings, which Greenwald & Associates conducted. It covered 1,406 family members caring for adults or children with a rare disease. […]

The post Those Who Care for Rare Disease Patients Face Burnout, First US Survey Shows appeared first on Pulmonary Hypertension News.

Read More
share on Twitter Like Those Who Care for Rare Disease Patients Face Burnout, First US Survey Shows on Facebook

Retrophin, Horizon Donate $3M Each to Rare Disease Institute at Children’s National

Mar 02, 2018 07:00 am | Larry Luxner

 

Retrophin and the U.S. subsidiary of Britain’s Horizon Pharma will each donate $3 million over a six-year period to the Rare Disease Institute (RDI) at Children’s National Health System in Washington, D.C., helping it to strengthen care available and expand as a “center of excellence” for rare disease patients. “We’re really proud of both these companies […]

The post Retrophin, Horizon Donate $3M Each to Rare Disease Institute at Children’s National appeared first on Pulmonary Hypertension News.

Read More
share on Twitter Like Retrophin, Horizon Donate $3M Each to Rare Disease Institute at Children’s National on Facebook

NIH Awards $2.8M Grant to PhaseBio Supporting Clinical Development of PB1046 in PAH

Mar 01, 2018 07:00 am | Patricia Inacio, PhD

 

PhaseBio's PB1046The National Institutes of Health (NIH) awarded a $2.8 million Fast Track Small Business Innovation Research (SBIR) grant to PhaseBio Pharmaceuticals to advance the clinical development of PB1046, the first sustained-release analogue of the natural vasoactive intestinal peptide (VIP), in patients with pulmonary arterial hypertension (PAH). In the first stage, the grant will support an ongoing […]

The post NIH Awards $2.8M Grant to PhaseBio Supporting Clinical Development of PB1046 in PAH appeared first on Pulmonary Hypertension News.

Read More
share on Twitter Like NIH Awards $2.8M Grant to PhaseBio Supporting Clinical Development of PB1046 in PAH on Facebook

Kidney Disease Patients with Pulmonary Hypertension Face Poorer Outcomes, Study Finds

Feb 28, 2018 07:00 am | Janet Stewart, MSc

 

Pulmonary hypertension kidney studyMany people with chronic kidney disease also have pulmonary hypertension, a condition that increases their risk of heart problems and death, a review of 16 studies found. Doctors refer to health problems that can damage the heart muscle as cardiovascular events. They include a heart attack, an irregular heartbeat, or a blood clot in the heart […]

The post Kidney Disease Patients with Pulmonary Hypertension Face Poorer Outcomes, Study Finds appeared first on Pulmonary Hypertension News.

Read More
share on Twitter Like Kidney Disease Patients with Pulmonary Hypertension Face Poorer Outcomes, Study Finds on Facebook

Minimally Invasive Surgery for Mitral Valve Disease to be Tested in Trial

Feb 27, 2018 10:30 am | Ana Pena

 

mitral valve diseaseA new cardiac surgical procedure to treat mitral valve disease, which is minimally invasive, does not require open-heart surgery, and offers faster recovery, is being tested in an upcoming clinical trial.  Mitral valve disease occurs when the heart’s mitral valve — which has two flaps that open and close to allow blood to flow — cannot […]

The post Minimally Invasive Surgery for Mitral Valve Disease to be Tested in Trial appeared first on Pulmonary Hypertension News.

Read More
share on Twitter Like Minimally Invasive Surgery for Mitral Valve Disease to be Tested in Trial on Facebook

Recent Posts

Remodulin Safe, Effective in Treating CTD-PAH for 12 Months, Observational Study Shows
Pulmonary Hypertension in CF Patients Worsens Lung Function but Not Survival, Analysis Says
Patient Advocacy Groups Worldwide Plan Events to Mark Rare Disease Day, Feb. 28
PAH Patients with Autoimmune Rheumatic Diseases Not at Higher Risk with Lung Transplant, Study Says

Copyright © 2018 BioNews Services, LLC, All rights reserved.
Email Marketing Powered by Mailchimp
unsubscribe from this list | update subscription preferences